AllPeptides.eu - Advanced Peptide Research
    Research-use-only hub
    1 variants

    Educational protocol hub

    FOXO4-DRI: protocol variants and reconstitution resources

    Educational hub for FOXO4-DRI, grouping 1 available protocol variant with links to the exact dosage and reconstitution pages.

    What this hub covers

    This page groups the available FOXO4-DRI protocol variants so readers can choose the exact vial-size guide without mixing formats.

    Reconstitution workflow

    Use the linked protocol pages and calculator resources to review concentration, diluent logic and unit conversions for the selected variant.

    Research-only context

    All information is educational and literature-focused. AllPeptides.eu does not sell peptides and does not provide medical advice.

    Available protocol variants

    Choose the exact guide you want to view.

    FOXO4-DRI

    10mg

    FOXO4-DRI dosing protocols focus on this innovative senolytic peptide (also known as Proxofim) designed to selectively target and eliminate senescent "zombie" cells. As a D-retro-inverso analog of a segment of the FOXO4 protein, it works by disrupting the FOXO4-p53 interaction in senescent cells, freeing p53 to trigger apoptosis and clearance of dysfunctional cells. This protocol outlines an intermittent subcutaneous approach.

    View protocol

    Related research resources

    Internal links that help readers and search engines understand this peptide topic cluster.

    References

    1. Nature Communications (2025) — The disordered p53 transactivation domain is a target for FOXO4 and FOXO4-DRI
      View Source
    2. Aging (Albany NY) (2020) — FOXO4-DRI alleviates testosterone insufficiency by targeting senescent Leydig cells
      View Source
    3. Cell (2017) — Targeted apoptosis of senescent cells restores tissue homeostasis
      View Source
    4. Frontiers in Bioengineering (2021) — Senolytic peptide FOXO4-DRI selectively removes senescent cells from human chondrocytes
      View Source
    5. PubMed / J Cell Mol Med (2022) — FOXO4 peptide targets myofibroblasts in pulmonary fibrosis
      View Source

    Educational and laboratory research information only. AllPeptides.eu does not sell peptides and does not provide medical advice or human-use instructions.

    Educational Navigator

    Educational reading navigator

    Find where to start in research peptide science through evidence, safety context and regulatory awareness.

    Covers

    Evidence levelsSafety contextRegulatory overviewLiterature readingResearch methodEducational reports
    5 min readEvidence-firstOpen access
    Open evidence framework

    New knowledge, new tools and selected updates from AllPeptides.eu